MRI in psoriatic arthritis: Insights into pathogenesis and treatment response

McQueen, Fiona; Dalbeth, Nicola; Doyle, Anthony

doi:10.1007/s11926-008-0049-y

Cited by 26 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of ultrasound and magnetic resonance imaging (MRI) in PsA has increased detection of enthesitis and improved the understanding of disease mechanisms [9,17,18]. MRI allows visualization of bone marrow oedema and osteitis commonly associated with entheseal disease, and ultrasound identifies tendon and ligament abnormalities demonstrating enthesitis [19,20,21,22]. Increased knowledge about the extent of tendon and ligament involvement in PsA prompted the suggestion that enthesitis is the primary event in PsA [22,23].…”

Section: Introductionmentioning

confidence: 99%

Enthesitis in Psoriatic Disease

McGonagle

Helliwell²,

Veale³

2012

Dermatology

View full text Add to dashboard Cite

Enthesitis is increasingly recognized as an important component in psoriatic arthritis (PsA). Improved imaging techniques have expanded our understanding of the role of enthesitis in PsA and provided methods for earlier detection and assessment. Increased knowledge about the extent of tendon and ligament involvement has led to the theory that enthesitis may be the primary event in PsA. Given the historical difficulties in detecting and measuring enthesitis, its inclusion as an endpoint in PsA trials has been limited. Current trial data suggest that tumour necrosis factor inhibitors can successfully treat PsA-related enthesitis, which may have implications for the long-term prognosis of PsA. In this article, we review methods for detecting and assessing enthesitis, current thinking regarding the role of enthesitis in the pathogenesis of PsA, and trial evidence for the treatment of PsA and, therefore, enthesitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Enthesitis in Psoriatic Disease

McGonagle

Helliwell²,

Veale³

2012

Dermatology

View full text Add to dashboard Cite

show abstract

“…US detects entheseal abnormalities, including tendon edema and thickening, tendon tears, bone erosions, enthesophytes, bursitis, and increased blood perfusion via power Doppler [99]. Magnetic resonance imaging (MRI) is useful to assess the spine and sacroiliac joints, because inflammation in these areas often is missed on x-rays [100].…”

Section: Evaluation Of the Patient With Psoriasis And Joint Painmentioning

confidence: 99%

Epidemiology and Natural History of Psoriatic Arthritis: an UpdateWhat Dermatologists Need to Know

2013

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can be associated with permanent joint damage and disability. Because patients may be unaware of the association of joint disease with psoriasis, dermatologists play an important role in identifying PsA. In this review, we discuss the natural history and key features of PsA, the epidemiology and hypothesized risk factors for disease, and screening tools that can be used in the dermatology clinic to aid in identifying which patients should be referred to a rheumatologist for further assessment.

show abstract

“…Osteitis has been frequently demonstrated in patients with PsA and other forms of SpA via MRI 18 19. There is a paucity of histological data providing information about the cellular constituency of these osteitic lesions.…”

Section: Pathophysiologymentioning

confidence: 99%

Psoriatic arthritis: update on pathophysiology, assessment and management

Mease

2011

Annals of the Rheumatic Diseases

147

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is classified as a spondyloarthropathy and characterised by synovitis, enthesitis, dactylitis and spondylitis usually manifesting as skin and nail psoriasis. Our understanding about the PsA disease state, its genetics, pathophysiology and comorbidities, as well as the ability to assess and treat the disease, has advanced as a result of significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures to assess the various clinical domains, and treatment trials with agents also used for diseases such as rheumatoid arthritis (RA) and psoriasis. Biological agents, especially the antitumour necrosis factors, have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease, resulting in amelioration of clinical symptoms, inhibition of structural damage and improvement of function and quality of life. Although there is considerable overlap with RA, there are some differences in pathophysiology and approach to assessment and management that are important to consider. This paper reviews these subjects, with an emphasis on recent data.

show abstract

MRI in psoriatic arthritis: Insights into pathogenesis and treatment response

Cited by 26 publications

References 49 publications

Enthesitis in Psoriatic Disease

Enthesitis in Psoriatic Disease

Epidemiology and Natural History of Psoriatic Arthritis: an UpdateWhat Dermatologists Need to Know

Psoriatic arthritis: update on pathophysiology, assessment and management

Contact Info

Product

Resources

About